These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 18008352)

  • 1. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Cho YK; Chung JW; Kim JK; Ahn YS; Kim MY; Park YO; Kim WT; Byun JH
    Cancer; 2008 Jan; 112(2):352-61. PubMed ID: 18008352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
    Marrero JA; Fontana RJ; Barrat A; Askari F; Conjeevaram HS; Su GL; Lok AS
    Hepatology; 2005 Apr; 41(4):707-16. PubMed ID: 15795889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and prognostic factors in patients with hepatocellular carcinoma.
    Martins A; Cortez-Pinto H; Marques-Vidal P; Mendes N; Silva S; Fatela N; Glória H; Marinho R; Távora I; Ramalho F; de Moura MC
    Liver Int; 2006 Aug; 26(6):680-7. PubMed ID: 16842324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
    Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome.
    Kim IS; Lim YS; Lee HC; Suh DJ; Lee YJ; Lee SG
    Aliment Pharmacol Ther; 2008 Feb; 27(4):338-45. PubMed ID: 18047564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
    Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
    Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
    Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma.
    Kondo K; Chijiiwa K; Nagano M; Hiyoshi M; Kai M; Maehara N; Ohuchida J; Nakao H; Ohkuwa Y
    Hepatogastroenterology; 2007; 54(77):1534-8. PubMed ID: 17708292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?
    Huo TI; Huang YH; Chiang JH; Wu JC; Lee PC; Chi CW; Lee SD
    Scand J Gastroenterol; 2007 Apr; 42(4):485-92. PubMed ID: 17454859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score.
    Chung H; Kudo M; Takahashi S; Hagiwara S; Sakaguchi Y; Inoue T; Minami Y; Ueshima K; Fukunaga T; Matsunaga T
    J Gastroenterol Hepatol; 2008 Mar; 23(3):445-52. PubMed ID: 17683486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.
    Stockland AH; Walser EM; Paz-Fumagalli R; McKinney JM; May GR
    Cardiovasc Intervent Radiol; 2007; 30(5):888-93. PubMed ID: 17619218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.